Who to call at AVENUE THERAPEUTICS, INC., and when
Fundz watches for the moments AVENUE THERAPEUTICS, INC. starts buying, and tells you who to reach.
- An alert the day AVENUE THERAPEUTICS, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AVENUE THERAPEUTICS, INC., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AVENUE THERAPEUTICS, INC.. With Fundz connected, it knows.
AVENUE THERAPEUTICS, INC.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
AI Executive Summary
AI-powered analysis of 8-K filing content
Avenue Therapeutics and its majority-owned subsidiary Baergic sold 100% of Baergic's equity to Axsome Therapeutics for a $0.3 million upfront payment, plus contingent milestones and royalties, transferring worldwide rights to BAER-101 (AXS-17). The shift makes Avenue's future value largely contingent on Axsome's development and commercial success.
Key Takeaways
Avenue and Baergic sold 100% of Baergic's equity to Axsome for a $0.3 million upfront payment (less transaction fees) and transferred worldwide development, manufacturing and commercial rights to BAER
Former Baergic stockholders may receive up to $2.5 million on first-indication development and regulatory milestones, $1.5 million for each later indication, up to $79 million on commercial sales mile
3 more takeaways
Related Filings (3)
3 more filings from AVENUE THERAPEUTICS, INC. in the last 90 days
Filing Overview
What This Means
AVENUE THERAPEUTICS, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.